CD19 and acute lymphoblastic leukemia: CD19-directed CAR-T cells have shown remarkable efficiency in the treatment of ALL and aggressive NHL (283, 289, 290) and, along the same line, new CD19-CAR-NK cells are showing effective anti-tumor activity with minor side effects (291).